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Background: An increased risk of venous thromboembolism has been reported in patients treated with
non-steroidal anti-inflammatory drugs (NSAIDs). We describe a case of acute portal vein thrombosis (PVT) in a
hepatitis C virus (HCV)-positive elderly patient following administration of indomethacin.
Case presentation: A 79-year-old HCV-positive man was hospitalized for severe abdominal pain, nausea and
vomiting, 15 days after starting indomethacin for back pain. Clinical signs and imaging evaluations disclosed a
picture of PVT. Indomethacin was discontinued, and the patient was started on fondaparinux and antithrombin. He
was discharged 15 days later due to improvement of his clinical conditions. Thirty days later, a follow-up ultrasound
did not show appreciable signs of PVT. The time elapsing between the start of analgesic therapy and PVT onset
suggests a role of indomethacin as the triggering agent. Indomethacin could have precipitated PVT by a
combination of at least two detrimental mechanisms: 1) direct action on liver vascular endothelium by inhibition of
prostacyclin biosynthesis; 2) damage to the intestinal mucosa, followed by inflammatory and pro-coagulant
activation of portal endothelium upon exposure to bacterial endotoxins.
Conclusions: This case can be of interest to physicians, who should exert caution when prescribing NSAIDs for
inflammatory pain in patients with background inflammatory dysfunctions of the portal vein endothelium.
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Portal vein thrombosis (PVT) is a thrombotic obstruction
of extrahepatic/intrahepatic portal venous system, asso-
ciated with local and systemic risk factors [1,2]. Local fac-
tors include: liver cirrhosis; hepatobiliary and pancreatic
malignancy; abdominal inflammation, infections and sur-
gery. Systemic risk factors encompass congenital and
acquired conditions. Congenital genotypes comprise: muta-
tions leading to antithrombin, protein C and protein S defi-
ciency, with loss of anticoagulant activity; mutations of
prothrombin and factor V Leiden genes, with gain of pro-
coagulant activity. Other inherited risk factors include high
levels of factors VIII, IX and XI, and hyperhomocysteine-
mia. Acquired risk factors are: myeloproliferative disorders;* Correspondence: marco.tuccori@gmail.com
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reproduction in any medium, provided the oranti-phospholipid syndrome; chronic inflammatory dis-
eases; obesity; oral contraceptive intake; pregnancy and
post-partum period [2-6].
Signs of acute PVT include: intestinal congestion, with
abdominal distension and pain; splenomegaly; ascites;
diarrhea; rectal bleeding; nausea and vomiting; anorexia;
fever; lactacidosis; sepsis. Chronic PVT can be asymp-
tomatic and characterized by portal cavernoma and por-
tal hypertension, cholestasis, splenomegaly, ascites,
gastro-esophageal varices, and pancytopenia [3].
This report describes a case of acute PVT in a hepa-
titis C virus (HCV)-positive elderly patient treated with
indomethacin for acute back pain.
Case presentation
On May 2010, a 79-year-old man was hospitalized for se-
vere postprandial abdominal pain, nausea and vomiting.
His medical history revealed a HCV-related mild non-
progressive chronic hepatitis (diagnosed in 1985; Child-
Pugh class A), never treated with anti-HCV therapy. Heal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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any other risk factor for thrombosis, such as smoking, al-
cohol intake or diabetes mellitus. Furthermore, his family
history was negative for bleeding or clotting disorders.
Since 1996, he was under treatment with lisinopril/hydro-
chlorothiazide (20/12.5 mg/day) for hypertension. Fifteen
days prior hospitalization, he was placed under treatment
with indomethacin (100 mg/day) for back pain. After
11 days of indomethacin therapy, the patient started to
complain of dyspepsia and abdominal pain, which wor-
sened rapidly leading to his hospitalization.
At admission, physical examination revealed a tractable
and painful abdomen. The patient reported a past sporadic
use of anti-inflammatory non-steroidal drugs (NSAIDs)
and no previous indomethacin intake. Blood tests showed
increased neutrophil count and alanine aminotransferase,
as well as moderate reductions of platelet count, activated
partial thromboplastin time (aPTT) and antithrombin III.
However, the prothrombin fragment F1+2 was not
assessed, and therefore a clear information about the sta-
tus of thrombin generation in this patient could not be
obtained. Notably, all these parameters were within their
normal ranges on a previous assessment, performed about
2 months earlier (i.e. 45 days before starting indometh-
acin), during a scheduled visit for monitoring his liver
function and general health condition. Relevant laboratory
parameters, recorded before and throughout the
hospitalization, are summarized in Table 1. AbdominalTable 1 Time course of laboratory parameters
Parameters (reference range) 2 months before admission
Red Blood Cell (4.5-6,00 106/μl) 4.82
White Blood Cell (4.5-10,00 103/μl) 9.15
Neutrophil (1.8-7.5 103/μl) 4.21
Platelet (150–400 103/μl) 322
AST (<40 U/l) 40
ALT (<41 U/l) 68
GGT (<60 U/l) 35
Total Bilirubin (<1.2 mEq/l) 1.11
Lactate dehydrogenase (135–225 U/l) -
Prothrombin activity (80-130%) 91
INR (0.87-1.12) 1.08
aPTT (25.1-36.5 sec) 30.9
aPTT Ratio (0.84-1.22) 1.01
Fibrinogen (200–450 mg/dl) 347
Antithrombin (83-128%) 95
D-dimer (< 0.3 mg/dl) -
C-Reactive Protein (< 0.500 mg/dl) -
Albumin (3.6-4.9 g/dl) 3.7
Abbreviations: AST aspartate aminotransferase; ALT alanine aminotransferase; GGT g
partial thromboplastin time; aPTT Ratio activated partial thromboplastin ratio.ultrasonography displayed: liver with regular margins and
fine heterogeneous structure; ascites involving all quad-
rants; increase in the diameter of portal vein (17 mm).
Both ascites and portal vein ectasia had not been detected
on recent past follow-up ultrasounds. Based on
leukocytosis, the clinicians hypothesized a bacterial infec-
tion, and started a treatment with ciprofloxacin (1000 mg/
day). In addition, indomethacin was discontinued, as its
possible involvement in the pathogenesis of abdominal
symptoms was suspected.
On day 4, a follow-up abdominal ultrasound confirmed
previous findings and displayed diffuse small bowel disten-
sion, without colonic involvement. An upper digestive en-
doscopy did not reveal erosions, ulcerations, mucosal
dysplasia or gastro-esophageal varices. On day 5, a viro-
logical blood screening was performed: cytomegalovirus
(CMV) IgM index was negative, while IgG levels were
positive, suggesting a past infection; anti-HCV antibody,
anti-HCV IgM and HCV core antigen were positive;
screening tests for hepatitis B virus were negative. A CT-
scan of chest and abdomen, with intravenous contrast
medium, revealed: massive thrombosis of portal trunk;
partial thrombosis of left portal vein branch and superior
mesenteric vein; mild ascites and ileal distension, with par-
ietal thickening; mild lymphadenopathies in the hepatic
hilum, celiac trunk and intercavo-aortic region; and no
sign of cancer or suspected lesions. A diagnosis of PVT
was then made, and a treatment with fondaparinuxAdmission Day 3 Day 6 Day 7 Day 8 Day 11 Day 13
5.53 4.70 4.46 - 4.17 4.15 -
18.94 15.49 11.26 - 9.16 8.37 -
16.36 11.29 7.51 - 5.70 4.37 -
121 126 183 - 255 367 -
40 33 85 - 69 36 -
74 53 131 - 108 61 -
36 24 35 - - - -
1.15 1.21 - - - - 0.22
211 244 240 - - - -
97 92 84 - 91 92 -
1.02 1.05 1.10 - 1.06 1.05 -
23.0 22.8 26.7 26.1 25.5 30.7 -
0.77 0.76 0.89 0.87 0.85 1.02 -
344 404 - 329 367 333 -
67 - 68 98 112 72 96
- - 5.74 3.29 2.86 1.23 1.07
- 13.700 - - - - -
- 2.8 - - - - 3.3
amma glutamyltransferase; INR international normalized ratio; aPTT activated
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started.
On day 7, a decrease in protein C (30%, reference range
72-146%) and protein S (30%, reference range 70-140%)
was detected. However, both parameters had never been
altered in past assessments. A genetic screening did not
show relevant mutations. Treatments with intravenous
antithrombin and oral ciprofloxacin were discontinued.
On day 11, a follow-up abdominal CT scan, with contrast
medium, displayed the persistence of thrombosis in portal
trunk, left portal vein branch and superior mesenteric
vein, with a reduction of intestinal distension and ascites.
Moreover, an abdominal Doppler confirmed an almost
complete PVT. Throughout the hospitalization, the pa-
tient had some episodes of red bloody stool excretion,
which were ascribed to his venous stasis.
On day 15, the severity of postprandial pain decreased
significantly, and the patient was discharged. After dis-
charge, he remained on fondaparinux for 12 days, and
then he was switched to warfarin with the goal of main-
taining the international normalized ratio within the
therapeutic range of 2–3. Thirty days later, a follow-up
ultrasound did not show appreciable signs of PVT. At 2
years from discharge, several follow-up visits have shown
that the patient persists on a stable mild liver disease
and he has not experienced further thrombotic events.
Discussion
In the present case, the time interval elapsing between
the start of indomethacin treatment and the event onset
suggests a role of this NSAID as the triggering agent of
PVT. According to the available medical information, in
this patient a prothrombotic condition has developed
during the 2 months ranging from the last blood ana-
lysis, performed before his admission, and the onset of
the abdominal symptoms leading to his hospitalization.
Therefore, the possibility that his mild chronic hepatitis
might have contributed to the occurrence of PVT cannot
be ruled out, even though his clinical history and his
previous records of coagulation parameters give a weak
support to the hypothesis that the underlying liver dis-
ease played a predominant pathogenic role in the devel-
opment of PVT. In this context, when considering the
possible association of indomethacin with PVT, two pos-
sible scenarios can be proposed: 1) the patient had a
subclinical prothrombotic state, and indomethacin acted
as the triggering agent of an overt PVT; 2) indomethacin
elicited primarily a prothrombotic state, which subse-
quently evolved towards PVT in the presence of a sus-
ceptible portal endothelium. Whatever the pathogenic
picture, it is important to consider that the patient
recovered promptly from PVT after indomethacin
dechallenge and the start of adequate anticoagulant ther-
apy. Moreover, the patient has not experienced anyfurther thrombotic event after about a two-year follow-
up from his discharge. A causality assessment of the as-
sociation of indomethacin therapy with the occurrence
of PVT, using the Naranjo probability scale, has scored
as possible [7].
In patients with severe chronic liver diseases, such as
cirrhosis, PVT can occur as a complication [8]. However,
our patient had a mild HCV-related chronic hepatitis
without signs of significant progression, as documented
by previous liver ultrasound patterns and lack of portal
hypertension and gastro-esophageal varices. Acute viral
infections, including CMV, represent other possible risk
factors for PVT, but, in our case, serologic evaluations
were consistent with a past CMV infection [9]. Other
systemic risk factors, including congenital defects, do
not appear to have played a relevant role in the occur-
rence of the present PVT event. Moreover, since the
levels of antithrombin III, platelet count, aPTT, protein
C and protein S were not altered in close proximity of
PVT onset, as shown by previous follow-up assessments
(Table 1), these deficiencies were likely a consequence of
PVT, rather than acting as contributing factors. In sup-
port of this contention, based on information from
current literature [10], the slight alterations of coagula-
tion parameters, recorded at admission, can be explained
by their consumption in the acute phase of thrombosis
and the reduced hepatic blood flow consequent to PVT.
In this light, the hypothesis of indomethacin as the trig-
gering agent of PVT would be strengthened further.
Besides a background chronic anti-hypertensive ther-
apy, the patient had been recently started on treatment
with indomethacin at the time of his symptom presenta-
tion. We therefore performed a MEDLINE search on
these drug treatments until December 2011. Key search
terms were: indomethacin, non-steroidal anti-inflamma-
tory drugs, NSAIDs, lisinopril, angiotensin-converting
enzyme inhibitors, ACE-Is, hydrochlorothiazide, diure-
tics, portal vein thrombosis, venous thrombosis and
thromboembolism. According to our literature search,
cases of indomethacin-related PVT have not been previ-
ously published. Nevertheless, we were able of retrieving
4 unpublished cases of PVT in patients taking indo-
methacin, by exploring the US Food and Drug Adminis-
tration and user community through the eHealthMe
searching system [11]. Moreover, a case–control study,
on the association between the use of NSAIDs, including
indomethacin, and the risk of venous thromboembolism,
reported an overall incidence rate ratio of 2.51 (95%
confidence interval [CI] 2.29-2.76). Of note, this study
showed also that in new users (first-ever exposure to
NSAIDs within 60 days before thrombotic event) the
risk increased to 4.56 (95% CI 3.85-5.40) [12]. In
addition, another case–control study highlighted an
increased risk of symptomatic pulmonary embolism in
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2.77). In this analysis, the risk was higher for traditional
non-selective NSAIDs over non-users and the overall
risk for NSAIDs was higher in the first 30 days of
exposure (odds ratio: 4.77, 95% CI 3.92-5.81), as com-
pared with chronic (<1 year; odds ratio: 1.83, 95% CI
1.47-2.28) or long-term use (>1 year; odds ratio: 2.14,
95% CI 1.48-3.09). This association can be partly
explained by the underlying medical conditions, which
may hamper the haemostatic balance [13]. For instance,
the intake of drugs inhibiting prostaglandin G2 synthase,
such as acetaminophen, during pregnancy has been
associated with an increased risk of preeclampsia and
thromboembolic events, and this effect could be the
consequence of a reduced prostacyclin production dur-
ing childbearing [14].
The present patient was a new indomethacin user, and
he disclosed a history of sporadic NSAID intake. In this
regard, at least two mechanisms might be advocated to
support a role of indomethacin as the triggering agent of
PVT (Figure 1). The first mechanism calls into play a
direct action of indomethacin on liver vascular endothe-
lium. Nygård et al. have demonstrated that the exposure
of cultured human umbilical vein cells (HUVEC) to
indomethacin, either alone or in the presence of lipo-
polysaccharide (LPS), led to an increase in procoagulant
activity [15]. In particular, LPS application to endothelial
cells resulted both in the induction of procoagulant ac-
tivity and the release of 6-keto-prostaglandin F1α (the
stable metabolite of prostacyclin) and prostaglandin E2,
as protective responses deputed to maintain the patency
of vascular blood flow. When HUVEC were cultured in
the presence of indomethacin and LPS, the prostanoidFigure 1 Proposed mechanisms accounting for the pro-thrombotic ac
thrombosis.production was suppressed, and the procoagulant re-
sponse increased up to the induction of pro-thrombotic
alterations [15]. In keeping with these findings, a study
on rats with portal hypertension showed that the con-
comitant administration of indomethacin and low-dose
aspirin resulted in a loss of antithrombotic protection by
aspirin on portal endothelium [16]. Based on this know-
ledge, it is conceivable that in the present patient, who
had a background of portal endothelial inflammation
maintained by chronic HCV infection [17], indometh-
acin did precipitate PVT by blocking the endothelial
biosynthesis of prostacyclin (Figure 1). A second mech-
anism can be related to the expected indomethacin-
induced intestinal mucosal damage, with consequent
enterobacterial translocation into the bowel wall and re-
lease of bacterial toxins into the portal circulation
[18,19]. Indeed, most of NSAIDs, including indometh-
acin, are endowed with acidic/lipophilic chemical struc-
tures, which allow them to elicit intestinal injuries, even
in the absence of upper digestive lesions, mainly by
means of topical damaging mechanisms [19,20]. As a
consequence, the abnormal increase in bowel mucosal
permeability allows bacteria, together with other toxic
agents (e.g., dietary macromolecules, bile acids, enzymes
of pancreatic juice), to penetrate into the enteric tissues
and activate inflammatory cascades [19,21]. In particular,
Gram- bacterial endotoxins, such as LPS, are potent in-
flammatory stimuli of vascular endothelium, where they
can induce the expression of adhesion molecules and tis-
sue factor (TF), interleukin-1 production, and stimula-
tion of arachidonic acid metabolism (Figure 1). TF acts
as a cell surface receptor for the circulating serine prote-
ase factor VIIa, and the formation of TF/factor VIIation of indomethacin in the present case of portal vein
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through the extrinsic pathway [17]. In addition, the older
age, as in this case, has been recognized as a specific risk
factor for the development of bowel injury in patients
taking NSAIDs. Indeed, a pooled analysis of three rando-
mized studies, performed on 34,701 elderly patients trea-
ted with etoricoxib or diclofenac for osteoarthritis/
rheumatoid arthritis, demonstrated an hazard ratio of
1.98 (95% CI 1.45-2.71) for the occurrence of intestinal
damage in patients aged over 65 years [22]. Of note, a
mucosal damage, elicited by indomethacin at the intes-
tinal level, may have contributed to: 1) the neutrophil
activation and high levels of C-reactive protein, which
were recorded at the patient admission; 2) the episodic
excretion of bloody stools, as observed in this patient
during his hospitalization [23]. Finally, it is noteworthy
that close correlations between inflammatory bowel dis-
eases/enteropathies and prothrombotic conditions, such
as PVT, have been well documented in the medical lit-
erature [2,3,24,25].
Conclusions
The present report suggests that in patients with back-
ground inflammatory conditions of portal vein endothe-
lium, indomethacin may precipitate thrombotic events,
likely through the inhibition of endothelial prostacyclin
biosynthesis and alterations of intestinal permeability.
Moreover, in these patients the older age may represent
an additional risk factor for NSAID related bowel dam-
age, thereby further increasing the risk of endothelial ac-
tivation and PVT. Accordingly, in these patients the
option of prescribing non-NSAID analgesics might be
considered when pain management is the main issue,
while caution should be exerted when NSAID prescrip-
tion is deemed to be unavoidable.
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